[go: up one dir, main page]

WO2024038980A1 - Souche de lactobacillus plantarum ku15120 ou son utilisation - Google Patents

Souche de lactobacillus plantarum ku15120 ou son utilisation Download PDF

Info

Publication number
WO2024038980A1
WO2024038980A1 PCT/KR2023/000288 KR2023000288W WO2024038980A1 WO 2024038980 A1 WO2024038980 A1 WO 2024038980A1 KR 2023000288 W KR2023000288 W KR 2023000288W WO 2024038980 A1 WO2024038980 A1 WO 2024038980A1
Authority
WO
WIPO (PCT)
Prior art keywords
strain
lactobacillus plantarum
culture
lactobacillus
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2023/000288
Other languages
English (en)
Korean (ko)
Inventor
이길웅
백현동
이나경
한경준
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ghbio Co Ltd
Original Assignee
Ghbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ghbio Co Ltd filed Critical Ghbio Co Ltd
Publication of WO2024038980A1 publication Critical patent/WO2024038980A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum

Definitions

  • the present invention relates to Lactobacillus plantarum KU15120 strain or its use.
  • Biochemical reactions constantly occur to supply energy in the living body, and most of the free radicals generated during this process are basically destroyed by the body's self-defense mechanism, but free radicals and The production of free radicals is the cause of various diseases such as cancer, as well as adult diseases and circulatory disorders.
  • antioxidants Substances that prevent damage to the body due to free radicals, which are the cause of various diseases, are called antioxidants. Antioxidants can be taken as drugs, but they can occur if exposed for a long time. You need to be careful about side effects.
  • adipocytes differentiate from preadipocytes into adipocytes, and as fat synthesis increases in adipocytes, they change into mature adipocytes and adipose tissue increases, leading to adipogenesis and adipogenesis. Inhibiting intracellular lipogenesis can reduce body fat accumulation.
  • transcription factors peroxisome proliferator-activated receptor gamma (PPARr), CCAAT/enhancer binding protein alpha (C/EBPa), sterol-regulatory element binding protein (SREBP), etc.
  • PPARr peroxisome proliferator-activated receptor gamma
  • C/EBPa CCAAT/enhancer binding protein alpha
  • SREBP sterol-regulatory element binding protein
  • Probiotics are defined as those that benefit the host's health when consumed in appropriate amounts (FAO/WHO, 2006). Probiotics must survive in the stomach to improve the intestinal environment (Franca et al., 2015). Probiotics are reported to have various functional properties such as antioxidant, immunomodulatory, cholesterol-lowering, anti-diabetic, and anti-obesity effects (Cheon et al., 2011; Lee et al., 2015).
  • the present invention relates to the Lactobacillus plantarum KU15120 strain, which can act as a probiotic and has probiotic activity, antioxidant, and body fat reduction effects.
  • Lactobacillus plantarum KU15120 strain isolated from radish kimchi, such as acid resistance, rash resistance, and intestinal adhesion ability, and killed it through antioxidant activity and heat treatment, and used this to suppress the differentiation of adipocytes to reduce body fat.
  • radish kimchi such as acid resistance, rash resistance, and intestinal adhesion ability
  • Korean Patent No. 1997362 and Korean Patent No. 2344838 were used.
  • the present invention was derived from the above-mentioned needs, and the present inventors discovered the antioxidant or anti-obesity effect of the Lactobacillus plantarum KU15120 strain, accession number KCCM 12752P, isolated from radish kimchi, and thus the present invention. Completed.
  • the present invention provides Lactobacillus plantarum KU15120 strain, accession number KCCM 12752P.
  • the strain may include the base sequence of SEQ ID NO: 1.
  • the present invention provides a probiotic composition
  • a probiotic composition comprising the Lactobacillus plantarum KU15120 strain with deposit number KCCM 12752P, its culture, a concentrate of the culture, or its dried product as an active ingredient.
  • the present invention provides an antioxidant composition
  • an antioxidant composition comprising the Lactobacillus plantarum KU15120 strain with deposit number KCCM 12752P, its culture, a concentrate of the culture, or its dried product as an active ingredient.
  • the present invention provides a pharmaceutical composition for preventing or treating obesity comprising Lactobacillus plantarum KU15120 strain with deposit number KCCM 12752P, a culture medium thereof, a concentrate of the culture medium, or a dried product thereof as an active ingredient.
  • the strain may inhibit adipocyte differentiation.
  • the present invention provides a food composition for preventing or improving obesity comprising the Lactobacillus plantarum KU15120 strain, accession number KCCM 12752P, its culture, a concentrate of the culture, or its dried product as an active ingredient.
  • the present invention provides a feed composition for preventing or improving obesity comprising the Lactobacillus plantarum KU15120 strain with deposit number KCCM 12752P, its culture, a concentrate of the culture, or its dried product as an active ingredient.
  • the present invention provides a method for preventing or improving obesity in non-human animals, comprising the step of administering Lactobacillus plantarum KU15120 strain, a culture medium thereof, a concentrate of the culture medium, or a dried product thereof, with accession number KCCM 12752P. .
  • Lactobacillus plantarum KU15120 strain, accession number KCCM 12752P of the present invention showed antioxidant or anti-obesity activity, it can be usefully used as a pharmaceutical, food or feed composition.
  • Figure 1 shows the base sequence of strain KU15120.
  • Figure 2 shows the family diagram of the KU15120 strain.
  • Figure 3 shows the intestinal adhesion ability of Lactobacillus strains. LGG, L. rhamnosus GG; KU15120, L. plantarum KU15120.
  • Figure 4 shows the antioxidant activity of Lactobacillus strains.
  • A DPPH
  • B ABTS
  • C b-carotene bleaching inhibition activity of LAB strains.
  • LGG L. rhamnosus GG; KU15120, L. plantarum KU15120.
  • Figure 5 shows the cytotoxic effect of Lactobacillus strains. ⁇ , 10 8 CFU/mL; ⁇ , 10 9 CFU/mL; LGG, L. rhamnosus GG; KU15120, L. plantarum KU15120.
  • Figure 6 shows the effect of inhibiting fat differentiation through Oil red O staining of Lactobacillus strains.
  • A Microscopic observation (i, Negative control; ii, Positive control; iii, LGG 10 8 CFU/mL; iv, KU15120 10 8 CFU/mL; v, LGG 10 9 CFU/mL; vi, KU15120 10 9 CFU/ mL)
  • B Measurement using colorimetric method. ⁇ , 10 8 CFU/mL; ⁇ , 10 9 CFU/mL; NC, negative control; PC, positive control; LGG, L. rhamnosus GG; KU15120, L. plantarum KU15120.
  • Figure 7 shows the effect of inhibiting the triglyceride content of Lactobacillus strains. ⁇ , 10 8 CFU/mL; ⁇ , 10 9 CFU/mL; NC, negative control; PC, positive control; LGG, L. rhamnosus GG; KU15120, L. plantarum KU15120.
  • Figure 8 shows the results of confirming the expression of the ability to suppress fat differentiation through RT-PCR and western blot methods of Lactobacillus strains.
  • A FAS mRNA
  • B C/EBPa mRNA
  • C PPARr mRNA
  • D Western blot analysis. ⁇ , 10 8 CFU/mL; ⁇ , 10 9 CFU/mL; NC, negative control; PC, positive control; LGG, L. rhamnosus GG; KU15120, L. plantarum KU15120.
  • the present invention provides Lactobacillus plantarum KU15120 strain, accession number KCCM 12752P.
  • the strain may include the base sequence of SEQ ID NO: 1.
  • the strain may be derived from kkakdugi kimchi, but is not limited thereto.
  • the strain may be a live strain or an attenuated strain (dead strain).
  • “Attenuated” means modifying a strain to reduce its pathogenicity. Attenuation is done for the purpose of reducing toxicity and other side effects when the strain is administered to a subject.
  • Attenuated strains can be prepared through various methods known in the art. For example, attenuation can be achieved by deleting or destroying virulence factors that allow the strain to survive in host cells. The deletion and destruction are well known in the art and are carried out, for example, by methods such as homologous recombination, chemical mutagenesis, irradiation mutagenesis, or transposon mutagenesis.
  • the present invention provides a probiotic composition
  • a probiotic composition comprising the Lactobacillus plantarum KU15120 strain with deposit number KCCM 12752P, its culture, a concentrate of the culture, or its dried product as an active ingredient.
  • culture medium in the present invention refers to the entire medium containing the strain, its metabolites, and extra nutrients obtained by culturing the strain for a certain period of time in a medium that can supply nutrients so that the strain can grow and survive in vitro. means, but is not limited to this.
  • probiotics of the present invention are live bacteria, that is, microorganisms that can survive in the gastrointestinal tract when ingested by humans or animals, and refer to microbial preparations that are effective in preventing or treating specific pathological conditions. In general, probiotics are effective in treating and improving various symptoms caused by abnormal fermentation of intestinal flora. When administered to humans and animals, they crowd and settle on the walls of the digestive tract and prevent harmful microorganisms from settling, causing lactic acid. It inhibits the growth of harmful microorganisms by lowering the intestinal pH.
  • the strain culture medium contains various antibacterial organic acids and non-proteinaceous antibacterial substances produced by the strain, so when included as an active ingredient in a probiotic composition, it can exhibit the same effect as a composition containing the strain.
  • the probiotic composition of the present invention is suitable for consumption by livestock along with the Lactobacillus genus lactic acid bacteria, inhibits the growth of harmful microorganisms upon ingestion, and contains other types of known microorganisms that have the activity of improving the balance of intestinal flora. may additionally be included.
  • the probiotic preparation of the present invention can be prepared and administered in various formulations and methods according to methods known in the art.
  • the Lactobacillus plantarum JDFM LP11 strain of the present invention, its culture, a concentrate of the culture, or a dried product thereof are mixed with a carrier commonly used in the pharmaceutical field to form powders, liquids and solutions. , it can be manufactured and administered in the form of tablets, capsules, syrup, suspension, or granules.
  • the carrier may include, for example, a binder, a lubricant, a disintegrant, an excipient, a solubilizer, a dispersant, a stabilizer, a suspending agent, a coloring agent, and a flavoring agent, but is not limited thereto.
  • the administered dose can be appropriately selected depending on the absorption rate of the active ingredient in the body, the inactivation rate, the excretion rate, the age, gender, species, condition, and severity of the disease of the recipient.
  • the probiotic composition of the present invention contains a strain or a culture medium thereof that is excellent in inhibition of intestinal pathogenic bacteria, acid resistance, bile resistance, etc., and thus has excellent infection inhibition and treatment effects of various intestinal pathogenic bacteria, and normalizes the host's intestinal flora. Not only can it prevent bacterial diseases, but it can also be usefully used in feed, food, and medicine as a probiotic composition such as an intestinal pathogenic bacteria inhibitor, immune enhancer, sterilizer, digestive agent, intestinal stimulant, and antidiarrheal agent.
  • the present invention provides an antioxidant composition
  • an antioxidant composition comprising the Lactobacillus plantarum KU15120 strain with deposit number KCCM 12752P, its culture, a concentrate of the culture, or its dried product as an active ingredient.
  • the present invention provides a pharmaceutical composition for preventing or treating obesity comprising Lactobacillus plantarum KU15120 strain with deposit number KCCM 12752P, a culture medium thereof, a concentrate of the culture medium, or a dried product thereof as an active ingredient.
  • prevention means suppressing or delaying the occurrence of a disease from its cause.
  • treatment means stopping the progression of damage by suppressing the progression and/or worsening of symptoms even if not completely cured, or improving some or all of the symptoms and leading toward healing.
  • composition of the present invention may further include appropriate carriers, excipients, and diluents commonly used in the preparation of the composition.
  • the pharmaceutical composition of the present invention can be used alone or in combination with methods using surgery, drug treatment, and biological response regulators for the prevention and treatment of diseases.
  • the pharmaceutical composition of the present invention can be formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injectable solutions according to conventional methods. , tablets, capsules, injections and liquid formulations are more preferable.
  • This formulation can be performed by a method commonly performed in the pharmaceutical field, and can be preferably formulated according to each disease or ingredient using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA.
  • Carriers, excipients, and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, and cellulose. , methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
  • diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations contain at least one excipient, such as starch, calcium carbonate, sucrose, or lactose ( It is prepared by mixing lactose, gelatin, etc. Additionally, in addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
  • excipient such as starch, calcium carbonate, sucrose, or lactose ( It is prepared by mixing lactose, gelatin, etc.
  • lubricants such as magnesium stearate and talc are also used.
  • Liquid preparations for oral administration include suspensions, oral solutions, emulsions, and syrups.
  • various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. there is.
  • Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories.
  • Non-aqueous agents and suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate.
  • injectable ester such as ethyl oleate.
  • As a base for suppositories witepsol, macrogol, tween, cacao, laurin, glycerogeratin, etc. can be used.
  • the preferred dosage of the composition of the present invention varies depending on the patient's condition and weight, degree of disease, drug form, administration route and period, but can be appropriately selected by a person skilled in the art. However, for desirable effects, the composition of the present invention may be included in an amount of 0.01 to 99.9% by weight, preferably 0.1 to 99% by weight, per day.
  • the daily dosage may be about 0.1 to 1,000 mg/kg, preferably 100 to 300 mg/kg.
  • the present invention provides a food composition for preventing or improving obesity comprising the Lactobacillus plantarum KU15120 strain with deposit number KCCM 12752P, a culture medium thereof, a concentrate of the culture medium, or a dried product thereof as an active ingredient.
  • the term “improvement” refers to any action in which obesity is improved or beneficially changed by administration of the composition of the present invention.
  • the composition of the present invention When using the composition of the present invention in food, the composition can be added as is or used together with other health functional foods or health functional food ingredients, and can be used appropriately according to conventional methods.
  • the mixing amount of the active ingredient can be appropriately determined depending on the purpose of use. In general, when producing a food or beverage, the composition of the present invention can be added in an amount of preferably 15 parts by weight or less, more preferably 10 parts by weight or less, based on the raw materials. However, in the case of long-term intake for the purpose of health control and hygiene, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
  • health functional food that can contain the composition of the present invention
  • specific examples include meat, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, and ice cream.
  • dairy products various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, etc., and can include all health functional foods in the conventional sense, and can include foods used as feed for animals.
  • Food auxiliary additives may be additionally added.
  • Food auxiliary additives include food auxiliary additives common in the art, such as flavoring agents, flavors, colorants, fillers, stabilizers, etc. .
  • natural carbohydrates examples include monosaccharides such as glucose, fructose, etc.; Disaccharides such as maltose, sucrose, etc.; and polysaccharides, such as common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • natural flavoring agents e.g., rebaudioside A, glycyrrhizin, etc.
  • synthetic flavoring agents sacharin, aspartame, etc.
  • the food composition of the present invention contains various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavors, colorants and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and It may include its salt, organic acid, protective colloidal thickener, pH adjuster, stabilizer, preservative, glycerin, alcohol, carbonating agent used in carbonated beverages, etc. In addition, it may contain pulp for the production of natural fruit juice, fruit juice drinks, and vegetable drinks. These ingredients can be used independently or in combination.
  • the above-mentioned health functional food is the same term as food for special health use (FoSHU), and is a medicine processed to efficiently exhibit bioregulatory functions in addition to nutritional supply, with high medical effects. It means food.
  • “function” means adjusting nutrients to the structure and function of the human body or obtaining useful effects for health purposes, such as physiological effects.
  • the food of the present invention can be manufactured by methods commonly used in the industry, and can be manufactured by adding raw materials and ingredients commonly added in the industry. Additionally, the food formulation can be manufactured without limitation as long as it is a formulation recognized as a food.
  • the food composition of the present invention can be manufactured in various types of formulations, and unlike general drugs, it is made from food as a raw material and has the advantage of not having side effects that may occur when taking the drug for a long period of time. It is also excellent in portability and can be used as a pharmaceutical composition according to the present invention.
  • the food composition can be taken as a supplement.
  • the present invention provides a feed composition for preventing or improving obesity comprising the Lactobacillus plantarum KU15120 strain with deposit number KCCM 12752P, its culture, a concentrate of the culture, or its dried product as an active ingredient.
  • the term "feed” may mean any natural or artificial diet, meal, etc., or a component of the meal, for or suitable for eating, ingestion, and digestion by animals.
  • the feed composition may include feed additives.
  • the above feed additives correspond to supplementary feed under the Feed Management Act.
  • the type of feed is not particularly limited, and feed commonly used in the art can be used.
  • Non-limiting examples of the feed include plant feeds such as grains, roots and fruits, food processing by-products, algae, fiber, pharmaceutical by-products, oils and fats, starches, cucurbits or grain by-products;
  • Examples include animal feed such as proteins, inorganic substances, fats and oils, minerals, single-cell proteins, zooplankton, or food. These may be used individually or in combination of two or more types.
  • the feed composition according to the present invention can be used by adding it to basic feed at a certain ratio.
  • the basic feed may consist of corn, soybean meal, whey, fish meal, molasses, salt, vitamin premix, mineral premix, etc.
  • the vitamin premix may consist of vitamin A, vitamin D, vitamin E, riboflavin, and niacin
  • the mineral premix may consist of, but is not limited to, manganese, iron, zinc, calcium, copper, cobalt, and selenium. .
  • the present invention provides a method for preventing or improving obesity in non-human animals, comprising the step of administering Lactobacillus plantarum KU15120 strain, a culture medium thereof, a concentrate of the culture medium, or a dried product thereof, with accession number KCCM 12752P. .
  • mammals including rats and livestock, without limitation, but refers to mammals other than humans.
  • the "administration” means introducing the composition of the present invention into an individual by any appropriate method, and the composition may be administered through various routes such as oral or parenteral. Specifically, for parenteral administration, injection methods such as external injection under the skin or intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection can be selected. Additionally, the number of administrations of the composition may be single or multiple administrations in amounts effective to the individual, but are not limited thereto.
  • administration route may be administered through any general or special route that can reach the target tissue.
  • Lactobacillus rhamnosus GG strain which is widely used as a commercial strain, was used as a standard strain. Lactobacillus Plantarum KU15120 (strain accession number: KCCM12752P) was used. These strains were cultured using MRS medium.
  • the pH was adjusted to 2.5 and the number of bacteria was cultured on TSB medium with 0.3% pepsin and TSB medium with 0.3% oxgall added at 37°C for 3 hours and 24 hours, respectively. was compared with the number of bacteria at 0 hours.
  • Lactobacillus Frantarum KU15120 was adjusted to a bacterial count of 1 ⁇ 10 5 CFU/mL, washed twice with PBS, and then zym A and zym B reagents were added and cultured at 37°C for 4 hours.
  • Antibiotic resistance was measured using disk diffusion assay according to CLSI (Clinical and Laboratory Standards Institute) standards. Eight antibiotics (ampicillin, gentamicin, kanamycin, streptomycin, tetracycline, ciprofloxacin, chloramphenicol, and doxycycline) were used. Lactobacillus bacteria were plated on TSA medium at a concentration of 10 6 CFU/mL, then a paper disk was placed and antibiotics were loaded. After culturing at 37°C for 24 hours, the clear zone was measured.
  • the Lactobacillus strain was inoculated into 1 ⁇ 10 5 cells/well of HT-29 cells and incubated at 37°C for 2 hours. After culturing, the cells were washed three times with PBS to wash away bacteria that were not attached to the HT-29 cells, and then the attached cells were removed with a 1% Triton X-100 solution and the number of bacteria was measured using TSA medium.
  • the antioxidant effect by DPPH free radical scavenging ability is one of the antioxidant measurement methods that removes DPPH free radicals and observes the color change of the DPPH solution.
  • the free radical scavenging ability was measured as follows. 0.2 mL of the sample and control were mixed with 1 mL of 100 ⁇ M DPPH (1,1-diphenyl-2-picrylhydrazyl), left at room temperature for 15 minutes, and the absorbance (optical density, OD) was measured at 517 nm. At this time, the DPPH free radical scavenging ability was calculated as follows.
  • the b-carotene bleaching assay tests the oxidation inhibitory ability of the active ingredient against b-carotene.
  • 3 mg of b-carotene, 66 ⁇ L of linoleic acid, and 300 ⁇ L of Tween 80 were dissolved in 15 mL of chloroform, the solvent was removed using a vacuum concentrator, and 150 mL of distilled water was added.
  • Lactobacillus plantarum KU15120 sample was reacted with 4.5 mL of b-carotene solution in a constant temperature water bath at 50°C for 2 hours, then the absorbance was measured at 470 nm, and the oxidation inhibition ability was calculated as follows.
  • b-carotene oxidation inhibition ability ⁇ (Absorbance of 2h sample - Absorbance of 2h control group)/(Absorbance of 0h control group - Absorbance of 2h control group) ⁇ ⁇ 100
  • the lactic acid bacteria strain is inoculated into MRS medium and cultured for 24 hours. After adjusting the number of bacteria to 1 ⁇ 10 9 CFU/mL, the cells were washed twice with PBS and then heat treated at 80°C for 30 minutes to prepare dead cells.
  • MTT methylthizol-2-yl-2,5-diphenyl tetrazoliumbromide assay was performed to measure whether Lactobacillus plantarum KU15120 induces cytotoxicity against 3T3-L1 (mouse embryo, ATCC CL-173).
  • Cell survival rate (%) ⁇ (cell survival rate for treatment group)/(cell survival rate for control group) ⁇ 100
  • 3T3-L1 cells (1.5 ⁇ 10 4 cells/dish) are inoculated on a 6 cm dish and cultured until adipocytes form confluence on the dish.
  • the strain was dissolved in DMEM medium (MDI medium) containing 0.5 mM 3-Isobutyl-1-methylxanthine (IBMX), 10 ⁇ M dexamethasone, and 5 ⁇ g/mL insulin, treated with adipocytes, and cultured for 2 days.
  • the strain was dissolved in DMEM medium containing 5 ⁇ g/mL insulin, treated with adipocytes, and cultured at 2-day intervals until the 6th day.
  • adipocytes To fix the differentiated adipocytes, they are treated with 10% formaldehyde solution and treated for 2 hours. After washing twice with PBS, treat with 0.5% oil red O solution and stain at room temperature for 20 minutes. Then, observe by photographing, wash twice with PBS, treat with isopropanol to elute the stained oil red O, and measure absorbance at 520 nm.
  • adipocyte differentiation was confirmed by measuring the triglyceride content in differentiated adipocytes. To collect proteins from differentiated adipocytes, they were centrifuged at 14,000 ⁇ g for 25 minutes, and then the proteins were collected and the triglyceride content was measured using a triglyceride quantification kit (BioVision).
  • 3T3-L1 cells which are preadipocytes, were differentiated and treated with Lactobacillus strains.
  • RNA primers Table 1
  • real-time PCR Real-time PCR
  • RNA purity was determined using Multiscan GO (Thermo Fisher Scientific, Waltham, MA, USA), and cDNA was converted using the Revertaid first strand cDNA synthesis kit (Thermo Fisher Scientific).
  • Semi-quantitative real-time PCR used SYBR Green PCR Master Mix, and PCR conditions were 20 ⁇ L total volume, 95°C for 2 min as initial denaturation; 40 cycle 95°C for 5 s as denaturation/60°C for 15 s as annealing and extension; It was set at 60°C for 10 min extension.
  • Acid resistance and bile resistance were measured under the conditions of artificial gastric fluid (pepsin 3 mg/mL, pH 2.5, 3 hours) and artificial bile fluid (oxgall 3 mg/mL, pH 7.0, 24 hours).
  • lactobacillus plantarum KU15120 was confirmed at 93.18% and 83.09%, respectively (Table 2).
  • Lactobacillus plantarum The KU15120 strain was confirmed to have excellent acid resistance and bile resistance.
  • Lactobacillus plantarum KU15120 showed excellent b-Galactosidase production ability and showed an enzyme production pattern similar to Lactobacillus rhamnosus GG strain.
  • Lactobacillus Plantarum The antibiotic resistance of KU15120 was tested according to CLSI standards, and antibiotic resistance can cause problems in terms of transfer of resistance genes. Lactobacillus Plantarum When compared to the industrial strain Lactobacillus rhamnosus GG, KU15120 was found to be resistant to streptomycin and chloramphenicol, and showed the same resistance to the others, so there was no concern about transfer of resistance genes (Table 4).
  • the intestinal adhesion ability of probiotics is one of the most important factors. Lactobacillus Plantarum of KU15120 It was confirmed that the intestinal attachment ability was 5.66% ( Figure 3), and considering that the standard for intestinal attachment ability of existing useful lactic acid bacteria is usually 1%, Lactobacillus plantarum KU15120 was confirmed to be a strain with excellent intestinal adhesion ability.
  • Lactobacillus plantarum Strain KU15120 showed a higher lipid oxidation inhibition ability at 37.61% than Lactobacillus rhamnosus GG (35.08%). When evaluated comprehensively, Lactobacillus Plantarum It can be seen that the KU15120 strain showed the most excellent antioxidant ability in the previous three experiments.
  • Lactobacillus Plantarum Both KU15120 and Lactobacillus rhamnosus GG strains showed no cytotoxicity against 3T3-L1 cells, preadipocytes, at two concentrations of 10 8 CFU/mL and 10 9 CFU/mL, and the lipolysis inhibitory effect was tested.
  • 3T3-L1 cells which are adipocytes, were treated with lactic acid bacteria and the inhibitory effect on differentiation of adipocytes was confirmed through Oil red O staining ( Figure 6).
  • Lactobacillus plantarum compared to PC (positive control) It was confirmed that there was less staining in the fat globules in KU15120 and Lactobacillus rhamnosus GG ( Figure 6A). In particular, it was confirmed that fat globules were reduced at 10 9 CFU/mL rather than 10 8 CFU/mL, and the comparative strains Lactobacillus rhamnosus GG and Lactobacillus plantarum It was confirmed that the size of the fat globules of KU15120 was similarly reduced. At a concentration of 10 9 CFU/mL, Lactobacillus rhamnosus GG and Lactobacillus plantarum KU15120 reduced it by 54.98% and 59.88%, respectively (Figure 6B).
  • Lactobacillus Plantarum KU15120 appears to have reduced triglyceride content by about 70.71% compared to PC, and the triglyceride content is about 0.46% lower than the comparative strain Lactobacillus rhamnosus GG, which is similar to Lactobacillus plantarum. KU15120 appears to have excellent ability to inhibit differentiation of adipocytes.
  • transcription factors such as peroxisome proliferator-activated receptor gamma (PPARr) and CCAAT/enhancer-binding protein alpha (C/EBPa) are transferred to adipocyte-specific proteins such as glucose transporter (GLUT4) and adipocyte-specific proteins.
  • adipocyte-specific proteins such as glucose transporter (GLUT4) and adipocyte-specific proteins.
  • GLUT4 glucose transporter
  • adipocyte-specific proteins such as glucose transporter (GLUT4)
  • adipocyte-specific proteins such as glucose transporter (GLUT4) and adipocyte-specific proteins.
  • GLUT4 glucose transporter
  • adipocyte-specific proteins adipocyte-specific proteins
  • aP2 specific fatty acid binding protein 2
  • FAS fatty acid synthase

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Husbandry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne la souche Lactobacillus plantarum KU15120 et son utilisation. La souche (Lactobacillus plantarum KU15120 a démontré des effets antioxydants et anti-obésité, ce qui a conduit à la présente invention.
PCT/KR2023/000288 2022-08-16 2023-01-06 Souche de lactobacillus plantarum ku15120 ou son utilisation Ceased WO2024038980A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020220102028A KR102506366B1 (ko) 2022-08-16 2022-08-16 락토바실러스 플란타럼 ku15120 균주 또는 이의 용도
KR10-2022-0102028 2022-08-16

Publications (1)

Publication Number Publication Date
WO2024038980A1 true WO2024038980A1 (fr) 2024-02-22

Family

ID=85511687

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2023/000288 Ceased WO2024038980A1 (fr) 2022-08-16 2023-01-06 Souche de lactobacillus plantarum ku15120 ou son utilisation

Country Status (2)

Country Link
KR (1) KR102506366B1 (fr)
WO (1) WO2024038980A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102857860B1 (ko) * 2023-09-11 2025-09-10 주식회사 에이치이엠파마 단백질 분해능이 우수한 락토바실러스 플란타룸(Lactobacillus plantarum) HEM20701 또는 이의 배양물, 파쇄물, 추출물을 유효성분으로 포함하는 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120034482A (ko) * 2010-10-01 2012-04-12 주식회사한국야쿠르트 지방세포 분화 유도에 관여하는 유전자의 발현을 억제함으로써 지방세포 분화 억제 효능을 갖는 락토바실러스 플란타룸 케이와이1032 및 이를 유효성분으로 함유하는 제품
KR20190051771A (ko) * 2018-07-30 2019-05-15 한국식품연구원 항비만 활성을 갖는 락토바실러스 플란타룸 WiKim0062 및 이를 포함하는 조성물
KR102011882B1 (ko) * 2017-12-26 2019-08-20 주식회사 종근당바이오 항비만 효과를 갖는 락토바실러스 플란타룸 k50 균주 및 이의 용도
KR102011883B1 (ko) * 2017-12-26 2019-08-20 주식회사 종근당바이오 항비만 효과를 갖는 락토바실러스 플란타룸 kc3 균주 및 이의 용도
KR102198827B1 (ko) * 2020-07-24 2021-01-05 주식회사 리부트라이프 신규 락토바실러스 플란타럼 균주 및 이를 포함하는 비만 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101512482B1 (ko) * 2013-10-21 2015-04-16 한국식품연구원 비만억제능이 우수한 신규한 락토바실러스 플랜타룸 q180 균주
WO2015122717A1 (fr) * 2014-02-17 2015-08-20 경희대학교 산학협력단 Nouvelles bactéries d'acide lactique possédant un effet inhibiteur sur l'obésité et leur utilisation
KR101997362B1 (ko) 2017-12-08 2019-07-08 비거트유산균 주식회사 락토바실러스 플란타룸 bk-021 균주 또는 이를 함유하는 항비만용 조성물
KR20190077714A (ko) * 2017-12-26 2019-07-04 주식회사 종근당바이오 항비만 효과를 갖는 락토바실러스 플란타룸 kc28 균주 및 이의 용도
KR102191774B1 (ko) * 2019-09-10 2020-12-16 단국대학교 천안캠퍼스 산학협력단 신규한 락토바실러스 플란타럼 mkha11 균주 및 이의 용도
KR102344838B1 (ko) * 2019-11-22 2021-12-28 이진영 항균 및 항비만 활성을 갖는 락토바실러스 플란타룸 yg1102 균주 및 이의 용도
KR102274678B1 (ko) * 2020-07-16 2021-07-12 (주)코엔바이오 신규한 락토바실러스 플란타룸 아종 플란타룸 Ｃｅｂ－ｋｃ－００７ 균주 및 이를 포함하는 항비만 효능을 가지는 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120034482A (ko) * 2010-10-01 2012-04-12 주식회사한국야쿠르트 지방세포 분화 유도에 관여하는 유전자의 발현을 억제함으로써 지방세포 분화 억제 효능을 갖는 락토바실러스 플란타룸 케이와이1032 및 이를 유효성분으로 함유하는 제품
KR102011882B1 (ko) * 2017-12-26 2019-08-20 주식회사 종근당바이오 항비만 효과를 갖는 락토바실러스 플란타룸 k50 균주 및 이의 용도
KR102011883B1 (ko) * 2017-12-26 2019-08-20 주식회사 종근당바이오 항비만 효과를 갖는 락토바실러스 플란타룸 kc3 균주 및 이의 용도
KR20190051771A (ko) * 2018-07-30 2019-05-15 한국식품연구원 항비만 활성을 갖는 락토바실러스 플란타룸 WiKim0062 및 이를 포함하는 조성물
KR102198827B1 (ko) * 2020-07-24 2021-01-05 주식회사 리부트라이프 신규 락토바실러스 플란타럼 균주 및 이를 포함하는 비만 예방 또는 치료용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE NA-KYOUNG, HAN KYOUNG JUN, PARK HOON, PAIK HYUN-DONG: "Effects of the Probiotic Lactiplantibacillus plantarum KU15120 Derived from Korean Homemade Diced-Radish Kimchi Against Oxidation and Adipogenesis", PROBIOTICS AND ANTIMICROBIAL PROTEINS, NEW YORK, NY ; HEIDELBERG : SPRINGER, NEW YORK, NY ; HEIDELBERG : SPRINGER, vol. 15, no. 3, 1 June 2023 (2023-06-01), New York, NY ; Heidelberg : Springer , pages 728 - 737, XP093140166, ISSN: 1867-1306, DOI: 10.1007/s12602-021-09885-2 *

Also Published As

Publication number Publication date
KR102506366B1 (ko) 2023-03-09

Similar Documents

Publication Publication Date Title
WO2019151843A1 (fr) Souche de lactobacillus plantarum kbl396 et son utilisation
WO2019199094A1 (fr) Nouvelle souche de bifidobacterium longum ou de lactobacillus rhamnosus ayant pour effet de prévenir ou de traiter l'obésité, et utilisation correspondante
WO2011010770A1 (fr) Nouvelle souche de lactobacillus plantarum et composition la contenant
WO2020075949A1 (fr) Nouvelle souche de lactobacillus plantarum atg-k2, atg-k6 ou atg-k8 et composition de prévention ou de traitement de la vaginite comprenant celle-ci
WO2021261632A1 (fr) Nouvelle souche de faecalibacterium prausnitzii eb-fpdk11 et utilisation associée
WO2010064777A1 (fr) Nouveau lactobacillus plantarum et composition le contenant
WO2019088379A1 (fr) Nouvelles bactéries lactiques et leur utilisation
WO2022265430A1 (fr) Utilisation en polythérapie d'une souche de lactobacillus fermentum et de cellules tueuses naturelles pour la prévention et le traitement de maladies métaboliques
WO2019226002A1 (fr) Souche de lactobacillus crispatus kbl693 et utilisation associée
WO2024048934A1 (fr) Nouvelle bactérie lactique lactiplantibacillus plantarum sko-001 pour réduire la graisse corporelle, et ses utilisations
WO2021261631A1 (fr) Nouvelle souche de picalibacterium prosnich eb-fpdk9 et utilisations associées
WO2023055188A1 (fr) Nouveaux probiotiques et utilisation associée
WO2020226467A1 (fr) Souche d'enterococcus lactis wik0107 ayant des effets de régulation des fonctions immunitaires et d'atténuation des maladies inflammatoires chroniques intestinales et son utilisation
WO2017047962A1 (fr) Nouveau lactobacillus et composition pour prévenir, atténuer ou traiter des maladies cérébrales dégénératives ou des troubles de la fonction cognitive
WO2025063597A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de l'obésité ou du syndrome de résistance à l'insuline, comprenant la souche lactobacillus plantarum hac03 et de la rutine
WO2016072655A1 (fr) Composition pour améliorer, traiter ou prévenir la constipation comprenant un produit fermenté renfermant des bactéries lactiques de graines de cassia comme ingrédient efficace, et son procédé de préparation
WO2022239916A1 (fr) Nouvelle souche de bifidobacterium longum et son utilisation
WO2022015033A1 (fr) Composition pour le traitement d'une maladie cérébrale comprenant pediococcus inopinatus ou des vésicules extracellulaires dérivées de celui-ci en tant que substance active
WO2010064778A1 (fr) Nouveau lactobacillus plantarum et composition le contenant
WO2024136036A1 (fr) Composition pour la prévention ou le traitement de l'arthrite, contenant lactobacillus brevis ku15147
WO2023229394A1 (fr) Souche de lactobacillus paracasei ou souche de lactobacillus plantarum issue du corps humain, présentant une activité de réduction de la graisse corporelle, et composition de mélange la comprenant
WO2024038980A1 (fr) Souche de lactobacillus plantarum ku15120 ou son utilisation
WO2025263981A1 (fr) Composition comprenant akkermansia sp.
WO2020139020A2 (fr) Kimchi pour la prévention ou le traitement de maladies associées à helicobacter pylori
WO2023068855A1 (fr) Composition pour le soulagement, la prévention ou le traitement du cancer à l'aide d'une souche de veillonella parvula ayant une activité anticancéreuse

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23854955

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23854955

Country of ref document: EP

Kind code of ref document: A1